

Reference:	FOI.16482.25
Subject:	Dermatology medicine
Date of Request:	29 January 2025

Requested:

1. For patients treated by the dermatology department with Dupilumab in the latest four months (September to December 2024), could you please tell us:
 - a. how many patients were treated in the previous 4-month period (May to August 2024) with Dupilumab?
 - b. how many patients were treated in the previous 4-month period (May to August 2024) with any of the following advanced therapies: abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab?
 - c. how many patients were treated in the previous 4-month period (May to August 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
 - d. how many patients were treated in the previous 4-month period (May to August 2024) with any other treatment? (e.g. Acitretin, Alitretin, Pimecrolimus, Tacrolimus, oral corticosteroids , topical steroids)

2. For patients treated by the dermatology department with Dupilumab in the four months from May to August 2024, could you please let us:
 - a. how many patients were treated in the subsequent 4-month period (September to December 2024) with Dupilumab?
 - b. how many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following advanced therapies: abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab?
 - c. how many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
 - d. how many patients were treated in the subsequent 4-month period (September to December 2024) with any other treatment? (e.g. Acitretin, Alitretin, Pimecrolimus, Tacrolimus, oral corticosteroids , topical steroids)

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of patients treated with the named medications, during the period 1 May to 31 August 2024, who have been treated with Dupilumab during the period 1 September to 31 December 2024.

Medication	Number
Dupilumab	84
Advanced Therapies (abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab)	0
Immunosuppressants (Methotrexate, Ciclosporin, Mycophenolate or Azathioprine)	11

<p>Other Treatment (Acitretin, Alitretoin, Pimecrolimus, Tacrolimus, oral corticosteroids, topical steroids)</p>	*
---	---

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

- The UHB provides within the table overleaf, the number of patients treated with the named medications, during the period 1 September 2024 to 31 December 2024, who have been treated with Dupilumab during the period 1 May to 31 August 2024.

Medication	Number
Dupilumab	84
Advanced Therapies (abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab)	6
Immunosuppressants (Methotrexate, Ciclosporin, Mycophenolate or Azathioprine)	0
Other Treatment (Acitretin, Alitretoin, Pimecrolimus, Tacrolimus, oral corticosteroids, topical steroids)	0